Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases

Bibliography

• LOTERSZTAJN S, JULIEN B, TEIXEIRA-CLERC F, GRENARD P, MALLAT A: Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. (2005) 45:605-628.
   PubMed Web of Science ®Google Scholar
• VAN SICKLE MD, DUNCAN M, KINGSLEY PJ et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310(5746):329-332.
   PubMed Web of Science ®Google Scholar
• PACHER P, BATKAI S, KUNOS G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. (2006) 58(3):389-462.
   PubMed Web of Science ®Google Scholar
• PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONSECA F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. (2000) 21(6):218-224.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, BIFULCO M, DE PETROCELLIS L: The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. (2004) 3(9):771-784.
   PubMed Web of Science ®Google Scholar
• MOORE SA, NOMIKOS GG, DICKASON-CHESTERFIELD AK et al.: From The Cover: Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc. Natl. Acad. Sci. USA (2005) 102(49):17852-17857.
   PubMed Web of Science ®Google Scholar
• ALEXANDER JP, CRAVATT BF: The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J. Am. Chem. Soc. (2006) 128(30):9699-9704.
   PubMed Web of Science ®Google Scholar
• THAKUR GA, NIKAS SP, MAKRIYANNIS A: CB1 cannabinoid receptor ligands. Mini-Rev. Med. Chem. (2005) 5(7):631-640.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW: CB2 receptor ligands. Mini-Rev. Med. Chem. (2005) 5(7):641-649.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. (1999) 6(8):635-664.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al.: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. (1998) 284(2):644-650.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, PIALOT F, CONGY C et al.: Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. (1996) 58(15):1239-1247.
   PubMed Web of Science ®Google Scholar
• LEDENT C, VALVERDE O, COSSU G et al.: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 283(5400):401-404.
   PubMed Web of Science ®Google Scholar
• ZIMMER A, ZIMMER AM, HOHMANN AG, HERKENHAM M, BONNER TI: Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA (1999) 96(10):5780-5785.
   PubMed Web of Science ®Google Scholar
• BUCKLEY NE, MCCOY KL, MEZEY E et al.: Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur. J. Pharmacol. (2000) 396(2-3):141-149.
   PubMed Web of Science ®Google Scholar
• GUZMAN M: Cannabinoids: potential anticancer agents. Nat. Rev. Cancer (2003) 3(10):745-755.
   PubMed Web of Science ®Google Scholar
• KLEIN TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. (2005) 5(5):400-411.
   PubMed Web of Science ®Google Scholar
• PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295(7):761-775.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet (2005) 365(9468):1389-1397.
   PubMed Web of Science ®Google Scholar
• DESPRES JP, GOLAY A, SJOSTROM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353(20):2121-2134.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ, FINER N, HOLLANDER P et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet (2006) 368(9548):1660-1672.
   PubMed Web of Science ®Google Scholar
• LANGE JHM, KRUSE CG: Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10(10):693-702.
   PubMed Web of Science ®Google Scholar
• MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. (2005) 12(12):1361-1394.
   PubMed Web of Science ®Google Scholar
• MUCCIOLI GG, WOUTERS J, CHARLIER C et al.: Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. J. Med. Chem. (2006) 49(3):872-882.
   PubMed Web of Science ®Google Scholar
• STEFFENS S, VEILLARD NR, ARNAUD C et al.: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 434(7034):782-786.
   PubMed Web of Science ®Google Scholar
• OFEK O, KARSAK M, LECLERC N et al.: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA (2006) 103(3):696-701.
   PubMed Web of Science ®Google Scholar
• KATHURIA S, GAETANI S, FEGLEY D et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9(1):76-81.
   PubMed Web of Science ®Google Scholar
• LICHTMAN AH, LEUNG D, SHELTON CC et al.: Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. (2004) 311(2):441-448.
   PubMed Web of Science ®Google Scholar
• MALLAT A, LOTERSZTAJN S: Endocannabinoids as novel mediators of liver diseases. J. Endocrinol. Investig. (2006) 29(3 Suppl.):58-65.
   PubMedGoogle Scholar
• BATKAI S, JARAI Z, WAGNER JA et al.: Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. (2001) 7(7):827-832.
   PubMed Web of Science ®Google Scholar
• ROS J, CLARIA J, TO-FIGUERAS J et al.: Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology (2002) 122(1):85-93.
   PubMed Web of Science ®Google Scholar
• BISWAS KK, SARKER KP, ABEYAMA K et al.: Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology (2003) 38(5):1167-1177.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-RODRIGUEZ CM, ROMERO J, PETROS TJ et al.: Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. (2004) 24(5):477-483.
   PubMed Web of Science ®Google Scholar
• JULIEN B, GRENARD P, TEIXEIRA-CLERC F et al.: Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 128(3):742-755.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA-CLERC F, JULIEN B, GRENARD P et al.: CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis. Nat. Med. (2006) 12(6):671-676.
   PubMed Web of Science ®Google Scholar
• MALLAT A, FOUASSIER L, PREAUX AM et al.: Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J. Clin. Invest. (1995) 96(1):42-49.
   PubMed Web of Science ®Google Scholar
• MALLAT A, GALLOIS C, TAO J et al.: Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J. Biol. Chem. (1998) 273(42):27300-27305.
   PubMed Web of Science ®Google Scholar
• GALLOIS C, HABIB A, TAO J et al.: Role of NF-κB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-α in human hepatic stellate cells. Involvement of cyclooxygenase-2. J. Biol. Chem. (1998) 273(36):23183-23190.
   PubMed Web of Science ®Google Scholar
• DAVAILLE J, GALLOIS C, HABIB A et al.: Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J. Biol. Chem. (2000) 275(44):34628-34633.
   PubMed Web of Science ®Google Scholar
• HEZODE C, ROUDOT-THORAVAL F, NGUYEN S et al.: Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology (2005) 42(1):63-71.
   PubMed Web of Science ®Google Scholar
• OSEI-HYIAMAN D, DEPETRILLO M, PACHER P et al.: Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. (2005) 115(5):1298-1305.
   PubMed Web of Science ®Google Scholar
• BENSAID M, GARY-BOBO M, ESCLANGON A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63(4):908-914.
   PubMed Web of Science ®Google Scholar
• SIEGMUND SV, UCHINAMI H, OSAWA Y, BRENNER DA, SCHWABE RF: Anandamide induces necrosis in primary hepatic stellate cells. Hepatology (2005) 41(5):1085-1095.
   PubMed Web of Science ®Google Scholar
• BOUABOULA M, PERRACHON S, MILLIGAN L et al.: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. (1997) 272(35):22330-22339.
   PubMed Web of Science ®Google Scholar
• PORTIER M, RINALDI-CARMONA M, PECCEU F et al.: SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. (1999) 288(2):582-589.
   PubMed Web of Science ®Google Scholar